Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis

BMJ (Online)

Volumn 355, Issue , 2016, Pages

  Huang, Yuli ^a   Cai, Xiaoyan ^a   Mai, Weiyi ^b   Li, Meijun ^a,c   Hu, Yunzhao ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DATA BASE; DISEASE ASSOCIATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MORTALITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; META ANALYSIS; RISK;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK;

EID: 84998892200     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i5953     Document Type: Article

References (86)

1. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011;108(Suppl):3B-24B. doi:10.1016/j.amjcard.2011.03.013.
2. World Health Organization (WHO) Consultation. Definition and diagnosis of diabetes and intermediate hyperglycaemia.2006http:// www.who.int/diabetes/publications/Definition%20and%20 diagnosis%20of%20diabetes-new.pdf.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5-20. doi:10.2337/diacare.26.2007.S5.
4. Rydén L. Grant PJ, Anker SD, et al. Authors/Task Force Members ESC Committee for Practice Guidelines (CPG) Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-87. doi:10.1093/eurheartj/eht108.
5. Forouhi NG, Balkau B. Borch-Johnsen K. et al. EDEG. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 2006;49:822-7. doi:10.1007/s00125-006-0189-4.
6. Kim SH, Chunawala L. Linde R. Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. J Am Coll Cardiol 2006;48:293-7. doi:10.1016/j.jacc.2006.03.043.
7. De Caterina R. Madonna R. Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship. Eur Heart J 2010;31:1159-62. doi:10.1093/eurheartj/ehp589.
8. Liu J. Grundy SM, Wang W. et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007;153:552-8. doi:10.1016/j. ahj.2007.01.003.
9. Laukkanen JA, Mäkikallio TH, Ronkainen K. Karppi J. Kurl S. Impaired fasting plasma glucose and type 2 diabetes are related to the risk of out-of-hospital sudden cardiac death and all-cause mortality. Diabetes Care 2013;36:1166-71. doi:10.2337/dc12-0110.
10. Rijkelijkhuizen JM, Nijpels G. Heine RJ, Bouter LM, Stehouwer CD, Dekker JM. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care 2007;30:332-6. doi:10.2337/ dc06-1238.
11. Levitzky YS, Pencina MJ, D'Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008;51:264-70. doi:10.1016/j. jacc.2007.09.038.
12. Khang YH, Cho SI, Kim HR. Risks for cardiovascular disease, stroke, ischaemic heart disease, and diabetes mellitus associated with the metabolic syndrome using the new harmonised definition: findings from nationally representative longitudinal data from an Asian population. Atherosclerosis 2010;213:579-85. doi:10.1016/j. atherosclerosis.2010.09.009.
13. Xu T. Liu W. Cai X. et al. Risk of Coronary Heart Disease in Different Criterion of Impaired Fasting Glucose: A Meta-Analysis. Medicine (Baltimore) 2015;94:e1740. doi:10.1097/MD.0000000000001740.
14. Lee M. Saver JL, Hong KS, Song S. Chang KH, Ovbiagele B. Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ 2012;344:e3564. doi:10.1136/bmj.e3564.
15. Ford ES, Zhao G. Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010;55:1310-7. doi:10.1016/j.jacc.2009.10.060.
16. Chatterton H. Younger T. Fischer A. Khunti K. Programme Development Group. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ 2012;345:e4624. doi:10.1136/bmj.e4624.
17. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34. doi:10.2337/dc09-9033.
18. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12. doi:10.1001/jama.283.15.2008.
19. Lorenzo C. Hartnett S. Hanley AJ, et al. Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab 2013;98:1622-30. doi:10.1210/ jc.2012-3185.
20. Mostafa SA, Khunti K. Srinivasan BT, Webb D. Gray LJ, Davies MJ. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Res Clin Pract 2010;90:100-8. doi:10.1016/j.diabres.2010.06.008.
21. Morris DH, Khunti K. Achana F. et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia 2013; 56:1489-93. doi:10.1007/ s00125-013-2902-4.
22. Wells GA, Shea B. O'Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/ oxford.asp.
23. Li M. Huang JT, Tan Y. Yang BP, Tang ZY. Shift work and risk of stroke: A meta-analysis. Int J Cardiol 2016;214:370-3. doi:10.1016/j. ijcard.2016.03.052.
24. Huang Y. Xu S. Hua J. et al. Association between job strain and risk of incident stroke: A meta-analysis. Neurology 2015;85:1648-54. doi:10.1212/WNL.0000000000002098.
25. Higgins JPT, Green S. eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://handbook.cochrane.org.
26. Ziff OJ, Lane DA, Samra M. et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451. doi:10.1136/bmj.h4451.
27. Brunström M. Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016;352:i717. doi:10.1136/bmj.i717.
28. Stengård JH, Tuomilehto J. Pekkanen J. et al. Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the Seven Countries Study. Diabetologia 1992;35:760-5.
29. Barzilay JI, Spiekerman CF, Wahl PW, et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 1999;354:622-5. doi:10.1016/S0140-6736(98)12030-5.
30. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405. doi:10.1001/archinte.161.3.397.
31. Mazza A. Pessina AC, Pavei A. Scarpa R. Tikhonoff V. Casiglia E. Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly. Eur J Epidemiol 2001;17:1097-104. doi:10.1023/A:1021216713504.
32. Saydah SH, Miret M. Sung J. Varas C. Gause D. Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001;24:1397-402. doi:10.2337/ diacare.24.8.1397.
33. Henry P. Thomas F. Benetos A. Guize L. Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension 2002;40:458-63. doi:10.1161/01.HYP.0000032853.95690.26.
34. Rodriguez BL, Abbott RD, Fujimoto W. et al. American Diabetes Association World Health Organization. The American Diabetes Association and World Health Organization classifications for diabetes: their impact on diabetes prevalence and total and cardiovascular disease mortality in elderly Japanese-American men. Diabetes Care 2002;25:951-5. doi:10.2337/diacare.25.6.951.
35. Lu W. Resnick HE, Jain AK, et al. Effects of isolated post-challenge hyperglycemia on mortality in American Indians: the Strong Heart Study. Ann Epidemiol 2003;13:182-8. doi:10.1016/ S1047-2797(02)00274-0.
36. Hunt KJ, Resendez RG, Williams K. Haffner SM, Stern MP. San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-7. doi:10.1161/01.CIR.0000140762.04598.F9.
37. Nakagami T. DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385-94. doi:10.1007/ s00125-004-1334-6.
38. Nakanishi N. Takatorige T. Fukuda H. et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 2004;64:59-70. doi:10.1016/j.diabres.2003.10.001.
39. Tai ES, Goh SY, Lee JJ, et al. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 2004;27:1728-34. doi:10.2337/diacare.27.7.1728.
40. Hiltunen L. Ten-year mortality and glucose tolerance status in an elderly Finnish population. Diabetes Res Clin Pract 2005;69:81-7. doi:10.1016/j.diabres.2004.11.004.
41. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90. doi:10.2337/diacare.28.2.385.
42. Wild SH, Smith FB, Lee AJ, Fowkes FG. Criteria for previously undiagnosed diabetes and risk of mortality: 15-year follow-up of the Edinburgh Artery Study cohort. Diabet Med 2005;22:490-6. doi:10.1111/j.1464-5491.2004.01433.x.
43. Kaarisalo MM, Räihä I. Arve S. Lehtonen A. Impaired glucose tolerance as a risk factor for stroke in a cohort of non-institutionalised people aged 70 years. Age Ageing 2006;35:592-6. doi:10.1093/ageing/ afl094.
44. McNeill AM, Katz R. Girman CJ, et al. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study. J Am Geriatr Soc 2006;54:1317-24. doi:10.1111/j.1532-5415.2006.00862.x.
45. Palmieri L. Donfrancesco C. Giampaoli S. et al. Favorable cardiovascular risk profile and 10-year coronary heart disease incidence in women and men: results from the Progetto CUORE. Eur J Cardiovasc Prev Rehabil 2006;13:562-70. doi:10.1097/01. hjr.0000221866.27039.4b.
46. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151-7. doi:10.1161/CIRCULATIONAHA.106.685628.
47. Nilsson PM, Engström G. Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects--a population-based study comparing three different definitions. Diabet Med 2007;24:464-72. doi:10.1111/j.1464-5491.2007.02142.x.
48. Pankow JS, Kwan DK, Duncan BB, et al. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007;30:325-31. doi:10.2337/dc06-1457.
49. Wang J. Ruotsalainen S. Moilanen L. Lepistö P. Laakso M. Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007;28:857-64. doi:10.1093/eurheartj/ehl524.
50. Wang JJ, Li HB, Kinnunen L. et al. How well does the metabolic syndrome defined by five definitions predict incident diabetes and incident coronary heart disease in a Chinese population? Atherosclerosis 2007;192:161-8. doi:10.1016/j.atherosclerosis.2006. 04.027.
51. Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB. Fasting and postchallenge hyperglycemia and risk of cardiovascular disease in Chinese: the Chin-Shan Community Cardiovascular Cohort study. Am Heart J 2008;156:996-1002. doi:10.1016/j.ahj.2008.06.019.
52. Jin M. Pan C. Tian H. et al Analysis of ten-year mortality in the male senile population with elevated fasting plasma glucose. Chinese J Endocrinol Metabol 2008;24:157-160. doi:10.3321/j. issn:1000-6699.2008.02.013
53. Kim NH, Pavkov ME, Looker HC, et al. Plasma glucose regulation and mortality in pima Indians. Diabetes Care 2008;31:488-92. doi:10.2337/dc07-1850.
54. Oizumi T. Daimon M. Jimbu Y. et al. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample--the Funagata study. Metabolism 2008;57:333-8. doi:10.1016/j.metabol.2007.10.007.
55. Tsai SP, Wen CP, Chan HT, Chiang PH, Tsai MK, Cheng TY. The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality. Diabetes Res Clin Pract 2008;82:148-56. doi:10.1016/j.diabres.2008.07.016.
56. Wannamethee SG. The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. Int J Obes (Lond) 2008;32(Suppl 2):S25-9. doi:10.1038/ijo.2008.32.
57. Hyvärinen M. Tuomilehto J. Mähönen M. et al. DECODE Study Group. Hyperglycemia and incidence of ischemic and hemorrhagic stroke-comparison between fasting and 2-hour glucose criteria. Stroke 2009;40:1633-7. doi:10.1161/STROKEAHA.108.539650.
58. Sung J. Song YM, Ebrahim S. Lawlor DA. Fasting blood glucose and the risk of stroke and myocardial infarction. Circulation 2009;119:812-9. doi:10.1161/CIRCULATIONAHA.108.776989.
59. Doi Y. Ninomiya T. Hata J. et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2010;41:203-9. doi:10.1161/STROKEAHA.109.564708.
60. Kokubo Y. Okamura T. Watanabe M. et al. The combined impact of blood pressure category and glucose abnormality on the incidence of cardiovascular diseases in a Japanese urban cohort: the Suita Study. Hypertens Res 2010;33:1238-43. doi:10.1038/hr.2010.174.
61. Magliano DJ, Söderberg S. Zimmet PZ, et al. Mortality, all-cause and cardiovascular disease, over 15 years in multiethnic mauritius: impact of diabetes and intermediate forms of glucose tolerance. Diabetes Care 2010;33:1983-9. doi:10.2337/dc10-0312.
62. Skriver MV, Borch-Johnsen K. Lauritzen T. Sandbaek A. HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), Denmark. Diabetologia 2010;53:2328-33. doi: 10.1007/ s00125-010-1867-9.
63. Sui X. Lavie CJ, Hooker SP, et al. A prospective study of fasting plasma glucose and risk of stroke in asymptomatic men. Mayo Clin Proc 2011;86:1042-9. doi:10.4065/mcp.2011.0267.
64. Yeboah J. Bertoni AG, Herrington DM, Post WS, Burke GL. Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2011;58:140-6. doi:10.1016/j.jacc.2011.03.025.
65. Ma SH, Park BY, Yang JJ, et al. Interaction of body mass index and diabetes as modifiers of cardiovascular mortality in a cohort study. J Prev Med Public Health 2012;45:394-401. doi:10.3961/jpmph.2012.45.6.394.
66. Deedwania P. Patel K. Fonarow GC, et al. Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: findings from a population-based cohort study. Int J Cardiol 2013;168:3616-22. doi:10.1016/j. ijcard.2013.05.038.
67. Kim HK, Kim CH, Kim EH, et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study. Diabetes Care 2013;36:328-35. doi:10.2337/dc12-0587.
68. Onat A. Can G. Çiçek G. Ayhan E. Doǧan Y. Kaya H. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults. Acta Diabetol 2013;50:519-28. doi:10.1007/s00592-011-0313-x.
69. Schöttker B. Müller H. Rothenbacher D. Brenner H. Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. Diabetologia 2013;56:92-100. doi:10.1007/s00125-012-2707-x.
70. Selvin E. Lazo M. Chen Y. et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation 2014;130:1374-82. doi:10.1161/CIRCULATIONAHA.114.010815.
71. Eastwood SV, Tillin T. Sattar N. Forouhi NG, Hughes AD, Chaturvedi N. Associations Between Prediabetes, by Three Different Diagnostic Criteria, and Incident CVD Differ in South Asians and Europeans. Diabetes Care 2015;38:2325-32. doi:10.2337/dc15-1078.
72. Gordon-Dseagu VL, Mindell JS, Steptoe A. et al. Impaired glucose metabolism among those with and without diagnosed diabetes and mortality: a cohort study using Health Survey for England data. PLoS One 2015;10:e0119882. doi:10.1371/journal.pone.0119882.
73. Paprott R. Schaffrath Rosario A. Busch MA, et al. Association between hemoglobin A1c and all-cause mortality: results of the mortality follow-up of the German National Health Interview and Examination Survey 1998. Diabetes Care 2015;38:249-56. doi:10.2337/dc14-1787.
74. Samaras K. Crawford J. Lutgers HL, et al. Metabolic Burden and Disease and Mortality Risk Associated with Impaired Fasting Glucose in Elderly Adults. J Am Geriatr Soc 2015;63:1435-42. doi:10.1111/jgs.13482.
75. Kim HK, Lee JB, Kim SH, et al. Association of prediabetes, defined by fasting glucose, HbA1c only, or combined criteria, with the risk of cardiovascular disease in Koreans. J Diabetes 2016;8:657-66. doi:10.1111/1753-0407.12343.
76. Huang Y. Cai X. Chen P. et al. Associations of prediabetes with all-cause and cardiovascular mortality: a meta-analysis. Ann Med 2014;46:684-92. doi:10.3109/07853890.2014.955051.
77. Hu G. DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newlydiagnosed diabetes. Diabetologia 2003;46:608-17. doi:10.1007/ s00125-003-1096-6.
78. Bullard KM, Saydah SH, Imperatore G. et al. Secular changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999-2010. Diabetes Care 2013;36:2286-93. doi:10.2337/ dc12-2563.
79. Xu Y. Wang L. He J. et al. 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-59. doi:10.1001/jama.2013.168118.
80. Nathan DM, Davidson MB, DeFronzo RA, et al. American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-9. doi:10.2337/dc07-9920.
81. Yoon U. Kwok LL, Magkidis A. Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials. Metabolism 2013;62:303-14. doi:10.1016/j.metabol.2012.07.009.
82. Yates T. Haffner SM, Schulte PJ, et al. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet 2014;383:1059-66. doi:10.1016/S0140-6736(13)62061-9.
83. Li G. Zhang P. Wang J. et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014;2:474-80. doi:10.1016/S2213-8587(14)70057-9.
84. Buysschaert M. Medina JL, Bergman M. Shah A. Lonier J. Prediabetes and associated disorders. Endocrine 2015;48:371-93. doi: 10.1007/ s12020-014-0436-2.
85. Ferrannini E. Definition of intervention points in prediabetes. Lancet Diabetes Endocrinol 2014;2:667-75. doi:10.1016/ S2213-8587(13)70175-X.
86. Harding JL, Soderberg S. Shaw JE, et al. All-cause cancer mortality over 15 years in multi-ethnic Mauritius: the impact of diabetes and intermediate forms of glucose tolerance. Int J Cancer 2012;131:2385-93. doi:10.1002/ijc.27503.